Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol. 2013 Dec; 14(13):1317-25.

View in: PubMed

subject areas

Adult
Aged
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
Breast Neoplasms
Chemotherapy, Adjuvant
Cyclophosphamide
Disease-Free Survival
Drug Administration Schedule
Epirubicin
Female
Fluorouracil
Humans
Kaplan-Meier Estimate
Lymph Nodes
Lymphatic Metastasis
Mastectomy
Middle Aged
Neoadjuvant Therapy
Neoplasm Grading
Neoplasm Staging
Paclitaxel
Puerto Rico
Receptor, ErbB-2
Stroke Volume
Time Factors
Trastuzumab
Treatment Outcome
United States

authors with profiles

KELLY K HUNT
AMAN U BUZDAR
FUNDA MERIC-BERNSTAM